Upstream Bio(UPB)
WALTHAM, MABiotechnology
Focus: Upstream Bio is a publicly traded biotech company focused on therapies for allergic and inflammatory conditions, with a pipeline anchored in respiratory and immunology indications. The company operates at a pre-revenue to early-revenue stage with ~51-200 employees and significant R&D investment.
Profile data last refreshed 22h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0
About Upstream Bio
AI assessmentNot HiringNo open roles listed right now. Follow Upstream Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Upstream Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$2M
FY2025
Pipeline & Clinical Trials
Help build intelligence for Upstream Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.